clinical

Videos

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD. 

Emerging therapies in management of AMD

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD). 

3 major risk factors of AMD

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

AMD: Learning the basics 

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

The state of dry, wet AMD in 2021

Articles

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Axitinib injectable suspension phase 1/2a trial enrolls first patients

Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.

AAO 2020: Considerations when using anti-VEGF for treating AMD

Modifier-25 same-day examinations are critical to the successful treatment and overall health and well being of these patients.

Same-day exams with anti-VEGF therapy key to QoL, cost savings for wet AMD 

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Study points to the possible role of addressing preprocedural anxiety

Easing patient comfort, pain perception of intravitreal injections

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats

Taking a deeper dive: Novel gene therapy approaches to treat ocular disease

Agreement would include global rights for investigational treatment, risuteganib, expected to help reverse vision loss due to dry AMD

Bausch Health to acquire option to purchase ophthalmology assets of Allegro 

Intravitreal gene therapy continues to be well tolerated; shows robust efficacy

Targeting AMD patient treatment burden

Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.

OCTA: Why the jury may still be out

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020 

Regenxbio: Dosing of first patient in Phase 2 AAVIATE trial for wet AMD 

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.

Deep learning algorithm proving accurate for AMD classification

A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.

Contrast sensitivity shows potential for measuring visual function loss in early AMD

Find out how the LIGHTSITE I results may pave the way for a new treatment approach.

What photobiomodulation may mean for patients with dry AMD

Subretinal transplantation of human embryonic stem cells (hESC)-derived retinal pigment epithelial (RPE) cells in patients with AMD and geographic atrophy (GA) appears well tolerated, according to date presented during ARVO 2020.

Stem cells for dry AMD with GA show promise in early study

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

AMD, DED most common retinal conditions in the United States

Early detection and anti-VEGF treatment of choroidal neovascularization (CNV) in the second eye leads to better mean final visual acuity (VA) with fewer injections at 1 year.

Early detection of CNV in second eye key to improving outcomes

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment